» Articles » PMID: 27657487

Cerenkov Radiation Induced Photodynamic Therapy Using Chlorin E6-Loaded Hollow Mesoporous Silica Nanoparticles

Overview
Date 2016 Sep 23
PMID 27657487
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Traditional photodynamic therapy (PDT) requires external light to activate photosensitizers for therapeutic purposes. However, the limited tissue penetration of light is still a major challenge for this method. To overcome this limitation, we report an optimized system that uses Cerenkov radiation for PDT by using radionuclides to activate a well-known photosensitizer (chlorin e6, Ce6). By taking advantage of hollow mesoporous silica nanoparticles (HMSNs) that can intrinsically radiolabel an oxophilic zirconium-89 (Zr, t = 78.4 h) radionuclide, as well as possess great drug loading capacity, Ce6 can be activated by Cerenkov radiation from Zr in the same nanoconstruct. In vitro cell viability experiments demonstrated dose-dependent cell deconstruction as a function of the concentration of Ce6 and Zr. In vivo studies show inhibition of tumor growth when mice were subcutaneously injected with [Zr]HMSN-Ce6, and histological analysis of the tumor section showed damage to tumor tissues, implying that reactive oxygen species mediated the destruction. This study offers a way to use an internal radiation source to achieve deep-seated tumor therapy without using any external light source for future applications.

Citing Articles

Radionuclide-labelled nanoparticles for cancer combination therapy: a review.

Sun N, Wang T, Zhang S J Nanobiotechnology. 2024; 22(1):728.

PMID: 39578828 PMC: 11585169. DOI: 10.1186/s12951-024-03020-3.


Self-Illuminating In Situ Hydrogel with Immune-Adjuvant Amplify Cerenkov Radiation-Induced Photodynamic Therapy.

Zhang X, Guo J, Zhou Z, Feng K, Liu H, Ruan Y Chem Biomed Imaging. 2024; 2(4):275-282.

PMID: 39473776 PMC: 11504187. DOI: 10.1021/cbmi.3c00098.


Inorganic nanoparticle-based treatment approaches for colorectal cancer: recent advancements and challenges.

Narayana S, Gowda B, Hani U, Shimu S, Paul K, Das A J Nanobiotechnology. 2024; 22(1):427.

PMID: 39030546 PMC: 11264527. DOI: 10.1186/s12951-024-02701-3.


New Opportunities and Old Challenges in the Clinical translation of Nanotheranostics.

Gawne P, Ferreira M, Papaluca M, Grimm J, Decuzzi P Nat Rev Mater. 2024; 8(12):783-798.

PMID: 39022623 PMC: 11251001. DOI: 10.1038/s41578-023-00581-x.


Investigation of Photodynamic Therapy Promoted by Cherenkov Light Activated Photosensitizers-New Aspects and Revelations.

Hubinger L, Wetzig K, Runge R, Hartmann H, Tillner F, Tietze K Pharmaceutics. 2024; 16(4).

PMID: 38675195 PMC: 11054706. DOI: 10.3390/pharmaceutics16040534.


References
1.
Khuri F, Nemunaitis J, Ganly I, Arseneau J, Tannock I, Romel L . a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000; 6(8):879-85. DOI: 10.1038/78638. View

2.
Redon C, Pilch D, Rogakou E, Sedelnikova O, Newrock K, Bonner W . Histone H2A variants H2AX and H2AZ. Curr Opin Genet Dev. 2002; 12(2):162-9. DOI: 10.1016/s0959-437x(02)00282-4. View

3.
Gambhir S . Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002; 2(9):683-93. DOI: 10.1038/nrc882. View

4.
Swisher S, Roth J, Komaki R, Gu J, Lee J, Hicks M . Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 2003; 9(1):93-101. View

5.
CHERENKOV P . Radiation from high-speed particles. Science. 1960; 131(3394):136-42. DOI: 10.1126/science.131.3394.136. View